The National Coalition for Cancer Survivorship (NCCS) has produced a new webinar discussing empathy and compassion in cancer care. In their presentation, Dr. Michael Crain and Claudio Pannunzio discuss three key aspects of compassionate care: "improving patient outcomes and satisfaction, decreasing health care costs, [and] reducing workplace burnout."
To learn more and view the webinar, click here.
Findings from the INCIPIENT study, an early phase I open-label study among participants with recurrent glioblastoma treated with intraventricularly delivered CARv3-TEAM-E T-cells, were recently published in the New England Journal of Medicine. The CARv3-TEAM-E T-cells "provides proof of principle that multiple surface antigens can be targeted simultaneously with the use of CAR T-cells and confirms that EGFR is a suitable immunotherapeutic target in glioblastoma."
To learn more about this study, click here.
Sources mentioned:
D-TORCH, a phase III randomized trial recently published in the Journal of Clinical Oncology, application of topical diclofenac gel, used in osteoarthritis, resulted in lower "grade 2 or 3 hand-foot syndrome rates compared with placebo in patients with breast and gastrointestinal cancers treated with oral capecitabine." Of the 131 patients who received topical diclofenac gel in the D-TORCH study, grade 2/grade 3 hand-foot syndrome occurred in only 3.8% of cases, compared to 15% in the placebo group.
To learn more about the D-TORCH study, click here.
Source mentioned:
Santhosh A, Sharma A, Bakhshi S, et al., on behalf of the D-TORCH Trial Investigators. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. JCO; Published online 27 February 2024. DOI: https://doi.org/10.1200/JCO.23.01730
Findings from the first population study assessing the risk of breast cancer specific mortality among male breast cancer patients, was recently published in JAMA Oncology. As a diagnosis of breast cancer in males is rare, the disease trajectory, particularly with regards to inclusion of male breast cancer patients in clinical trials, has not been well studied. However, "the median age at diagnosis is substantially higher in men than in women, and patients with male breast cancer are more likely to have regional nodal involvement."
To learn more about this study, click here.
Source mentioned: Leone J, Hassett MJ, Freedman RA, et al. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. JAMA Oncology; Published online 29 February 2024. doi:10.1001/jamaoncol.2023.7194
